Clicky

 

Intelligence » Melanoma » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

FDA Grants Priority Review For Opdivo In Patients With Advanced Melanoma

Tuesday, October 17, 2017 -- NewsU.S. Food and Drug Administration (FDA) accepts Bristol-Myers Squibb’s application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review.Contributed Author: Bristol-Myers Squibb CompanyTopics: Drug Development

Classifying dermoscopic patterns of naevi in a case-control study of melanoma

Tuesday, October 17, 2017 -- by Seamus R. McWhirter, David L. Duffy, Katie J. Lee, Glen Wimberley, Philip McClenahan, Natalie Ling, Marco Ardigo, Helmut Schaider, H. Peter Soyer, Richard A. Sturm Changes in dermoscopic patterns of naevi may be associated with melanoma; however, there is no consensus on which dermoscopic classification system is optimal. To determine whether different classification systems give comparable results and can be combined for analysis, we applied two systems to a case-control study of melanoma with 1037 participants: 573 classified using a “1/3 major feature” system, 464 classified based on rules of appearance, and 263 classified with both criteria. There was strong correlation for non-specific (Spearman R = 0.96) and reticular (Spearman R = 0.82) naevi, with a slight bias

Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma

Tuesday, October 17, 2017 -- Mario Sznol, MD, of the Yale University School of Medicine in New Haven, Connecticut, discusses melanoma clinical trial results just published in the Journal of Clinical Oncology.